Q2 EPS Estimates for Vir Biotechnology Cut by HC Wainwright

Posted by Stanley Muller on May 12th, 2026

Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) – Stock analysts at HC Wainwright dropped their Q2 2026 earnings estimates for shares of Vir Biotechnology in a note issued to investors on Friday, May 8th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of $0.56 per share for the quarter, down from their prior forecast of $0.73. HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($1.96) per share. HC Wainwright also issued estimates for Vir Biotechnology’s Q3 2026 earnings at ($0.71) EPS, Q4 2026 earnings at ($0.60) EPS, FY2026 earnings at ($1.55) EPS, Q1 2027 earnings at ($0.63) EPS, Q2 2027 earnings at ($0.68) EPS, Q3 2027 earnings at ($0.49) EPS, Q4 2027 earnings at ($0.45) EPS, FY2027 earnings at ($2.22) EPS, FY2028 earnings at ($1.57) EPS, FY2029 earnings at ($1.16) EPS and FY2030 earnings at ($0.36) EPS.

A number of other research firms have also issued reports on VIR. Needham & Company LLC boosted their price target on shares of Vir Biotechnology from $14.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, February 24th. Raymond James Financial raised shares of Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price objective on the stock in a research report on Tuesday, February 24th. Barclays upped their price objective on shares of Vir Biotechnology from $26.00 to $30.00 and gave the company an “overweight” rating in a research note on Tuesday, February 24th. Morgan Stanley set a $23.00 price objective on shares of Vir Biotechnology in a research note on Friday. Finally, Wall Street Zen lowered shares of Vir Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.25.

Read Our Latest Analysis on VIR

Vir Biotechnology Price Performance

VIR stock opened at $9.29 on Tuesday. Vir Biotechnology has a 52-week low of $4.16 and a 52-week high of $11.66. The company’s 50 day simple moving average is $9.59 and its 200-day simple moving average is $7.60. The firm has a market capitalization of $1.50 billion, a P/E ratio of -2.97 and a beta of 1.70.

Vir Biotechnology (NASDAQ:VIR – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.84). Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 53.31%. The firm had revenue of ($0.03) million for the quarter, compared to analyst estimates of $55.49 million. During the same quarter in the prior year, the firm earned ($0.88) EPS.

Institutional Trading of Vir Biotechnology

A number of hedge funds have recently bought and sold shares of VIR. AQR Capital Management LLC boosted its holdings in Vir Biotechnology by 2,088.4% in the 1st quarter. AQR Capital Management LLC now owns 268,297 shares of the company’s stock valued at $1,739,000 after purchasing an additional 256,037 shares during the period. Jacobs Levy Equity Management Inc. bought a new stake in Vir Biotechnology in the 1st quarter valued at $359,000. Goldman Sachs Group Inc. boosted its holdings in Vir Biotechnology by 43.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock valued at $4,813,000 after purchasing an additional 225,544 shares during the period. Woodline Partners LP boosted its holdings in Vir Biotechnology by 245.6% in the 1st quarter. Woodline Partners LP now owns 466,737 shares of the company’s stock valued at $3,024,000 after purchasing an additional 331,701 shares during the period. Finally, Focus Partners Wealth boosted its holdings in Vir Biotechnology by 15.3% in the 1st quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock valued at $125,000 after purchasing an additional 2,566 shares during the period. 65.32% of the stock is owned by institutional investors.

Insider Activity

In related news, EVP Verneuil Vanina De sold 13,700 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $9.82, for a total transaction of $134,534.00. Following the completion of the sale, the executive vice president directly owned 112,982 shares of the company’s stock, valued at approximately $1,109,483.24. This represents a 10.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Backer Marianne De sold 72,559 shares of the company’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $9.16, for a total transaction of $664,640.44. Following the sale, the chief executive officer directly owned 948,145 shares of the company’s stock, valued at approximately $8,685,008.20. This represents a 7.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 257,816 shares of company stock valued at $2,377,698 in the last quarter. 16.00% of the stock is currently owned by corporate insiders.

Key Stories Impacting Vir Biotechnology

Here are the key news stories impacting Vir Biotechnology this week:

Positive Sentiment: HC Wainwright raised its FY2029 EPS estimate for Vir Biotechnology, suggesting a slightly better long-term earnings outlook. Results: Vir Biotechnology, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts
Positive Sentiment: The analyst firm kept a Buy rating and reiterated a $20 price objective, indicating confidence that VIR can recover from current losses. Results: Vir Biotechnology, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts
Neutral Sentiment: Recent coverage also pointed to valuation upside tied to the Astellas partnership and pipeline progress, which may support the shares if execution improves. A Look At Vir Biotechnology (VIR) Valuation After The Astellas Partnership And Pipeline Progress
Negative Sentiment: HC Wainwright cut earnings estimates for FY2026, FY2027, FY2030, and several interim quarters, signaling continued losses and slower profitability than previously expected. Results: Vir Biotechnology, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts
Negative Sentiment: The firm also lowered near-term estimates for Q2 2026, Q3 2026, Q4 2026, Q1 2027, Q2 2027, Q3 2027, and Q4 2027, reinforcing concerns that earnings will remain under pressure in the coming years. Results: Vir Biotechnology, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts
Negative Sentiment: Another article noted that Vir Biotechnology delivered a surprise loss, which helps explain why analysts have been adjusting forecasts downward. Results: Vir Biotechnology, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts

Vir Biotechnology Company Profile

(Get Free Report)

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.